Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

** Please note that online appointment request does not guarantee an immediate booking as this depends on the schedule of the oncologist. The appointment will be booked at the erliest possible time, and you wil be contacted by our front office staff.

Close Appointment form

Stefanos Labropoulos

  • Home
  • Stefanos Labropoulos

Stefanos Labropoulos

Clinical Specialties

  • Medical Oncology
  • Hematology

Current Title

  • Associate Director, 3rd Oncology Department Hygeia Hospital Athens Greece
  • Co-founder, Contemporary Oncology Team, Athens Greece

  • MD National University of Athens Medical School Graduated magna cum laude, Greece, 1988
  • Residency in Internal Medicine at University of Illinois at Chicago, 1992 – 1995
  • Fellowship in Hematology Oncology and Transplantation at University of Minnesota, Minneapolis, 1995 – 1998
  • Fellowship in Hematology and Medical Oncology at Virginia Commonwealth University / Massey Cancer Center Virginia, 1998 – 1999

  • Greek Ministry of Public Health,1999
  • American Board of Internal Medicine, 1995
  • American Board of Internal Medicine, Hematology & Medical Oncology Boards, 1998. Recertified Medical Oncology, 2014
  • European Medical Oncology Board, 2003 and 2014

  • Full medical license in Greece (ISA),1988
  • State of Illinois, 1995
  • Commonwealth of Virginia, 2001

  • Greece
    • Athens Medical Association
    • Hellenic Society of Medical Oncology
  • European Union
    • European Society for Medical Oncology
  • United States of America
    • American College of Physicians
    • American Society of Hematology
    • American Society of Clinical Oncology

  • Good Clinical Practice for Investigational Site Staff training, 2015
  • Sub-Investigator in Phase II-IV Clinical Studies

Dr. Labropoulos is the principal or co-author of over 18 publications in peer review / high impact academic and professional publications. He is also the author of four chapters in textbooks and specialized edited books.

A complete list of Publications

  • A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCL patients. Molecular and Cellular Probes 2001, Vol 15, pp 243-247
  • Continuation of Trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A prospective analysis of 80 cases by the Hellenic Cooperative Oncology Group: Clinical Breast Cancer 2003; 4, pp 120-5
  • Gefitinib as treatment for non-small cell lung cancer. BJC 2003 ;89 Suppl 2, pp532
  • Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer. BMC Cancer. 2004 Sep 7;4:61.
  • Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anti-Cancer Drugs 2005,16 pp 461-6
  • Treatment of non-small cell lung cancer with gefitinib (Iressa ZD 1839): the Greek experience with a compassionate –use program. Anti-Cancer Drugs 2005 Feb ;16 pp 91-198
  • Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat. 2005 Jul; 92(1):1-9.
  • Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia. Eur J Haematol. 2006 Mar; 76(3):230-6.
  • Hypermethylation of the p15INK4B gene promoter in B-chronic lymphocytic leukemia. Am J Hematol. 2007 Sep;82(9):824-5.
  • Imatinib in the treatment of dermatofibrosarcoma protuberans. Biologics 2007 Dec;1 (4):347-53
  • Elucidation of the transmission of a novel mutation in BRCA 1 (1125 del CT) in a family with multiple cases of breast cancer. Cancer Genomics Proteomics 2009 Jul-Aug; 6:215-7
  • Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 2009 Oct ;15 :6258-66
  • MBD2 contributes to developmental silencing of the human ε-globin gene. Blood Cells Mol Dis. 2011 Mar 15; 46(3):212-9. doi: 10.1016/j.bcmd.2011.01.001. Epub 2011 Feb 4.
  • Breast cancer chapter in: Advancements in Internal Medicine publication ZHTA. 2001 and 2006 (in Greek)
  • Geriatric Oncology in: Basic principles of Cancer Treatment, edition 2006 (Greek)
  • Geriatric treatment of Breast cancer in: Breast Cancer, edition 2007 (Greek)
  • Immunologic therapy of cancer in: Pathology of the Lymphatic System, Athens 2011

Scientific Interests

  • Epigenetics


  • Ethiopia, 2007


  • Scientific resident of the year, annual awards University of Illinois, Chicago
  • Award by the University of Addis Ababa, Ethiopia for voluntary work in May 2007


Dr. Labropoulos speaks English and French besides Greek.